Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716208 · ClinicalTrials.gov registry record · Phase 2
Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma
A Phase 2 study, sponsored by Joseph Tuscano.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01716208 is a Phase 2 study that has completed, run by Joseph Tuscano. The registered enrollment target is 12 participants.
The verdict
NCT01716208, a Phase 2 study, has completed, sponsored by Joseph Tuscano.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
It has been shown that many patients with lymphoma or chronic lymphocytic leukemia (CLL)have low levels of complement. Several drugs have been approved by the Food and Drug Administration (FDA) for use in this cancer. However, these drugs are often used as combination therapies which means two or more drugs are part of the treatment. Many people, especially elderly patients, cannot put up with the use of multiple drugs because of the side effects. The main purpose of this study is to see if patients respond to therapy with human plasma (known as fresh frozen plasma or FFP) and ofatumumab. Another purpose of the study is to find out if this therapy will increase chances of getting rid of leukemia. This study will also look at the levels of complement in your blood. The levels of complement may allow better understanding of whether increasing the levels of complement by giving FFP may help control leukemia.
Interventions
- DRUG Ofatumumab + Fresh Frozen Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-01-14 |
| Est. Completion | 2020-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01716208
The ClinicalTrials.gov registry entry for NCT01716208 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joseph Tuscano, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ofatumumab + Fresh Frozen Plasma is the first listed.
NCT01716208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01716208 about?
NCT01716208 is a clinical study titled "Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma". It has been shown that many patients with lymphoma or chronic lymphocytic leukemia (CLL)have low levels of complement. Several drugs have been approved by the Food and Drug Administration (FDA) for use in this cancer. However, these drugs are often used as combination therapies which means two or mo...
What is the current status of trial NCT01716208?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2013-01-14. Estimated completion is 2020-10-01.
What interventions are being tested in trial NCT01716208?
The interventions under investigation include: Ofatumumab + Fresh Frozen Plasma (DRUG).
Who is sponsoring clinical trial NCT01716208?
This trial is sponsored by Joseph Tuscano, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.